Vertex grows CF franchise as combos move forward

The outlook for Vertex is bright, as positive data from experimental combination treatments could eventually position the biotech to reach 90% of cystic fibrosis patients.

By Ned Pagliarulo • Oct. 26, 2017

Sanofi debuts brand campaign to play up role as health partner

Using the new corporate signature "Empowering Life," the French drugmaker seeks to unify its five business around a central message. 

By Suzanne Elvidge • Oct. 25, 2017

Explore the Trendline➔

Commercialization

New drugs for obesity and Alzheimer’s look set to become blockbusters, reshaping pharma marketing strategies just as many current top-sellers near looming patent cliffs.

By BioPharma Dive staff

With Advair copies looming, GSK keeps focus on new drugs

Recent approvals of Trelegy Ellipta and Shingrix should help bolster the drugmaker's prospects in key areas as it prepares for a generic hit. 

By Ned Pagliarulo • Oct. 25, 2017

Expanded label opens new market for Alexion's Soliris

The FDA has now approved the blockbuster drug as a treatment for patients with generalized myasthenia gravis, an uncommon neruomuscular disorder.

By Jacob Bell • Oct. 24, 2017

Eyes on Alcon as Novartis notches modest growth

Analysts are focused on the possible divestiture of the eye care business, while Novartis' newer drugs help make up for competition to Gleevec. 

By Ned Pagliarulo • Oct. 24, 2017

US Spinraza sales cause concern among Biogen investors

Though the rare disease drug raked in $271 million in the third quarter, stateside revenues and inventory remained stagnant.

By Jacob Bell • Oct. 24, 2017

Biosimilars could save US $150B over next decade

A recent report suggests using biosimilars over branded biologics could boost access — a trend the FDA hopes to encourage by educating stakeholders on the copycat drugs.

By Suzanne Elvidge • Oct. 24, 2017

Merck slashes sales staff in cost-cutting exercise

In a therapeutic shift, the big pharma is cutting 1,800 sales staff by eliminating three sales teams, but is creating a new salesforce of over 900.

By Suzanne Elvidge • Oct. 23, 2017

Despite increased spending, orphan drugs still small piece of US medicines market

While the number of approved rare disease treatments has surged, the niche products account for a small share of overall expenditure on medicines.

By Ned Pagliarulo • Oct. 18, 2017

Anthem leaves Express Scripts behind to roll out its own PBM

Named IngenioRx, the new pharma middleman is scheduled to debut in 2020.

By Jacob Bell • Oct. 18, 2017

CVS aims to cut patient drug costs through EHR collaboration

The PBM will work with electronic health records provider Epic to give prescribers better visibility into lower cost options. 

By Suzanne Elvidge • Oct. 18, 2017

Trevena cuts workforce 30% to free up cash

In a "re-positioning" effort, the company is focusing more resources on getting its pain med Olinvo approved and commercialized.

By Jacob Bell • Oct. 13, 2017

Merck's StayWell nabs mobile app maker MedHelp

The deal helps to strengthen Merck’s role in diabetes management.

By Meg Bryant • Oct. 12, 2017

Long rundowns of side effects can make drugs seem less risky, study finds

Paradoxically, exhaustively listing risks in DTC ads can dilute consumer perception of the severity of a drug's side effects, according to new research.

By Ned Pagliarulo • Oct. 11, 2017

Lupin expands US presence with $150M Symbiomix deal

While branded drugs remain a small contributor to Lupin's overall sales, the Indian generics maker hopes acquiring Symbiomix will help build its specialty business.

By Ned Pagliarulo • Oct. 11, 2017

Clovis looks to expand label for PARP inhibitor

Securing approval to expand use of Rubraca for a broader group of patients will be a key step if Clovis is to catch up with its PARP rivals.

By Suzanne Elvidge • Oct. 11, 2017

Insys calls opioid allegations 'unfair'

After several states brought lawsuits against the company, Insys responded by noting the steps it has taken to fix past mistakes.

By Lisa LaMotta • Oct. 9, 2017

Flexion secures US approval for osteoarthritis drug

The biotech is highlighting the drug as a non-opioid, non-surgical option for knee pain associated with the chronic condition. 

By Ned Pagliarulo • Oct. 9, 2017

Report: Amazon near a decision about pharmacy sales

As the e-commerce giant weighs whether to jump into the volatile space, shares of drug store retailers Walgreens, CVS Health and Rite Aid all fell on Friday.

By Daphne Howland • Oct. 9, 2017

PCSK9 court saga drags on for Sanofi, Regeneron and Amgen

A court has allowed for the continued sale of Praluent, while the companies continue to battle it out over the flailing market. 

By Suzanne Elvidge • Oct. 6, 2017

Insys hit with lawsuit, fine for opioid marketing

The latest litigation against Insys comes from the state of New Jersey, which is accusing the company of "titanic greed and corporate irresponsibility."

By Lisa LaMotta • Oct. 5, 2017

Motif delivers more strong data on its antibiotic

In another late-stage study, the company's iclaprim demonstrated non-inferiority to standard-of-care in treating bacterial skin infections. 

By Jacob Bell • Oct. 5, 2017

CVS to use prescription labeling from Target designer

Despite accolades and the popularity of designer Deborah Adler's Target Pharmacy labeling, CVS didn't adopt it when it took over Target's pharmacy business — until now.

By Daphne Howland • Oct. 5, 2017

Allergan to Congress: The IPR system needs fixing

In a recently penned letter, CEO Brent Saunders defended his company's decision to protect Restasis patents by working with the Saint Regis Mohawk Tribe.

By Jacob Bell • Oct. 4, 2017

Generic makers fail to stop drug pricing law

The Association for Accessible Medicines' lawsuit has failed to halt Maryland's House Bill 631 going into effect this weekend.

By Suzanne Elvidge • Oct. 4, 2017